EI
DAWN

Ellevest Inc’s Day One Biopharmaceuticals DAWN Stock Holding History

Ellevest Inc’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13
Closed -$280 – 1932
2022
Q4 		$280 Sell
13
-10
-43% -$205 ﹤0.01% 1695
2022
Q3 		$0 Buy
23
+13
+130% +$276 ﹤0.01% 1664
2022
Q2 		$0 Buy
+10
New +$103 ﹤0.01% 1451

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ellevest Inc's DAWN Position: Q1 2023 in Review

Ellevest Inc sold out of Day One Biopharmaceuticals (DAWN) in Q1 2023, closing a stake of 13 shares — an estimated $280 sold.

Ellevest Inc first reported a position in DAWN in Q2 2022 and held it in 3 quarters. The position peaked at $280 in Q4 2022. 126 funds tracked by Wall St. Rank hold DAWN as of Q1 2023.

  • Ellevest Inc reported no remaining Day One Biopharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ellevest Inc sold 13 Day One Biopharmaceuticals shares in Q1 2023, an estimated $280.
  • Ellevest Inc first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 3 quarters.
  • Ellevest Inc's Day One Biopharmaceuticals position peaked at $280 in Q4 2022.
  • 126 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2023.

Based on Ellevest Inc's 13F filing for Q1 2023, filed 4 May 2023.